Alnylam Pharmaceuticals Valuation
Is ALNY * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ALNY * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ALNY * (MX$2453) is trading below our estimate of fair value (MX$5020.74)
Significantly Below Fair Value: ALNY * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ALNY *?
Other financial metrics that can be useful for relative valuation.
What is ALNY *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$18.64b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 9.5x |
Enterprise Value/EBITDA | -155x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ALNY *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 10x | ||
BGNE BeiGene | 6.2x | 19.1% | US$16.8b |
GMAB Genmab | 7.4x | 14.9% | kr.133.4b |
ARGX argenx | 15.4x | 23.5% | €20.5b |
NTRA Natera | 10.9x | 13.9% | US$13.0b |
ALNY * Alnylam Pharmaceuticals | 9.3x | 19.6% | Mex$18.6b |
Price-To-Sales vs Peers: ALNY * is good value based on its Price-To-Sales Ratio (9.3x) compared to the peer average (10x).
Price to Earnings Ratio vs Industry
How does ALNY *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: ALNY * is good value based on its Price-To-Sales Ratio (9.3x) compared to the Global Biotechs industry average (10.3x).
Price to Sales Ratio vs Fair Ratio
What is ALNY *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 9.3x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALNY *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.